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Abstract 
GA101, also known as obinutuzumab or Gazyva (Gazyvaro), is a glycoengineered type II 
humanized antibody that targets the CD20 antigen expressed at the surface of B-cells. This 
novel anti-CD20 antibody is currently assessed in clinical trials with promising results as a 
single agent or as part of therapeutic combinations for the treatment of B-cell malignancies. 
Detailed understanding of the mechanisms of GA101-induced cell death is needed to get 
insight into possible resistance mechanisms occurring in patients. Although multiple in vitro 
and in vivo mechanisms have been suggested to describe the effects of GA101 on B-cells, 
currently available data are ambiguous. The aim of our study was to clarify the cellular 
mechanisms involved in GA101-induced cell death in vitro, and more particularly the 
respective roles played by lysosomal and mitochondrial membrane permeabilization. Our 
results confirm previous reports suggesting that GA101 triggers homotypic adhesion and 
caspase-independent cell death, two processes that are dependent on actin remodeling and 
involve the production of reactive oxygen species. With respect to lysosomal membrane 
permeabilization (LMP), our data suggest that lack of specificity of available antibodies 
directed against cathepsin B may have confounded previously published results, possibly 
challenging current LMP-driven model of GA101 action mode. 
Key words: 
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1. Introduction 
The CD20 protein, which is selectively expressed on precursor and mature B cells, has been 
validated as a target antigen for immunotherapy in B-cell malignancies. Rituximab, a Type I 
chimeric (human/mouse) IgG1 anti-CD20 antibody, was approved for the treatment of 
patients with B-cell non-Hodgkin lymphoma (NHL) as far back as the late nineties. It has 
been shown that rituximab binding to CD20 may cause cell death through three distinct 
mechanisms: (1) activation of complement-dependent cytotoxicity (CDC) after CD20 
relocalization into lipid rafts; (2) initiation of antibody-dependent cellular cytotoxicity 
(ADCC) and phagocytosis (ADCP) via Fc region binding to Fcγ receptors (FcγR) on innate 
immune effectors such as natural killer cells and macrophages; (3) direct induction of 
programmed cell death (PCD) [1-5]. Addition of rituximab to standard chemotherapy 
improves the clinical outcome of patients with NHL and chronic lymphocytic leukemia (CLL). 
However, a significant percentage (30-50%) of rituximab-treated patients fail to achieve 
complete or partial remission, and many experience disease relapse [3, 4, 6-14]. This has 
prompted research efforts to develop novel anti-CD20 antibodies with improved functional 
properties and greater clinical efficacy [5]. 
Obinutuzumab (GA101) is a Type II humanized mouse IgG1κ anti-CD20 antibody with a 
glycoengineered Fc fragment [15] to enhance Fc receptor binding affinity (in particular for 
FcγRIIIa). GA101 is currently under phase III clinical trials for the treatment of patients with 
NHL [16, 17] and has been approved for patients with previously untreated CLL [18-21]. In 
vivo studies have indicated superior anti-lymphoma activity for this third-generation anti-
CD20 antibody over rituximab [15, 22, 23]. Positional mapping showed that the epitope of 
GA101 partially overlaps the epitope of rituximab and extends towards the C-terminus of 
CD20 which contributes to the high binding affinity of GA101 for CD20 [5, 15, 24]. Protein 
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tomography analysis indicated that, contrary to rituximab bivalent binding to CD20, GA101 
preferentially binds to CD20 monovalently, which favors intra- rather than inter-CD20 
tetramer binding [5, 24, 25]. Both structural features and CD20-binding characteristics of 
GA101 make it different from rituximab in terms of mode of action: GA101 does not provoke 
CD20 relocalization in lipid rafts and subsequent CDC, but induces stronger homotypic 
adhesion (HA) and direct PCD [5, 15]. In addition, the glycoengineered fragment of GA101 
leads to enhanced ADCC and ADCP activity [1, 2, 15, 26, 27]. 
Although rituximab has been demonstrated to induce apoptosis of non-Hodgkin lymphoma 
cell lines in vitro [28, 29], evidence from numerous investigations does not appear to support 
this observation especially in the in vivo context [30-37]. For its part, GA101 is thought to 
trigger non-apoptotic (necrotic-like) cell death without the need of CD20 cross-linking. The 
current proposal on the sequence of events leading to GA101-induced "programmed necrosis" 
is as follows: (i) binding of GA101 to the extracellular domain of CD20 followed by HA, (ii) 
peripheral reorganization of the actin cytoskeleton, (iii) lysosomal membrane 
permeabilization (LMP), (iv) cathepsin B release to the cytosol, (v) NADPH oxidase (NOX)-
mediated (i.e., non-mitochondrial) reactive oxygen species (ROS) production, and (iv) loss of 
plasma membrane integrity [38, 39].  
However, not all cells die by caspase-independent cell death upon exposure to GA101 as both 
procaspase-3 overexpression and caspase-3 activation were reported in the human non-
Hodgkin's lymphoma B cell line RL cells [40]. Moreover, cell surface exposure of 
phosphatidylserine (PS) was consistently observed upon GA101 treatment in a variety of cell 
lines, raising the possibility of a transition from apoptosis to secondary necrosis for a fraction 
of the B-cell population [15, 40]. In fact, there is evidence that GA101 can induce 
mitochondrial membrane permeabilization (MMP) [39, 41], but this event was considered as 
secondary to LMP and cathepsin B release [39]. The ability of GA101 to trigger necrosis, 
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apoptosis or both may reflect features of the same cell death pathway that converge on 
mitochondria and/or lysosomes in a cell type- and/or context-specific manner. Alternatively, 
the choice of GA101-induced cell death by necrosis or apoptosis may depend on which of the 
two events occurs first: LMP or MMP. 
Motivated by these concerns, we sought to undertake an accurate kinetic analysis of LMP and 
MMP in GA101-treated B cells. The present study was also carried out with the premise that 
detailed understanding of the role of mitochondria and lysosomes in GA101-induced cell 
death can provide insights for GA101 use in therapy and help overcome possible resistance 
mechanisms.  
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2. Material and Methods 
2.1. Cell culture and treatments 
Raji or SUDHL-4 cells were cultured in RPMI 1640 medium (PAA) containing 10% fetal calf 
serum, 2mM L-glutamine, 100 units penicillin, and 100µg streptomycin. Cells were seeded at 
0.5 x 10
6
 cells/mL and treated with 10µg/ml of GA101 (provided by Roche Pharma) or 
rituximab (MabThera Lot: H0623, Roche) for different periods of time.  
2.2. HA assay 
Cells were seeded in 8-well imaging chambers (Zell-Kontakt, Germany) and recorded every 
5min for 24h using phase-contrast time-lapse videomicroscopy (inverted Axiovert 100M, 
Zeiss) in an environment at 37
o
C with 5% CO2. In other experiments, microphotographs of 
untreated cells and cells receiving pre-treatment with different inhibitors or treatment by 
GA101 were taken using an inverted Leica microscope. Images were processed using ImageJ 
software. 
2.3. Cell death analysis by flow cytometry 
In a first set of experiments, cells were treated with GA101 or Rituximab for 6, 12, 24 and 
48h or left untreated. Treated cells were harvested by centrifugation at 1800rpm for 5 min and 
resuspended in 100µL of Annexin V/propidium iodide labeling solution (Annexin-V-FLUOS 
Staining kit, Roche). Cells were then analyzed by flow cytometry (Becton Dickinson, LSR II) 
after an incubation period of 15min in the dark at room temperature. 
In a second set of experiments, cells were first pre-treated with different inhibitors for 1 or 2h: 
Latrunculin B (Enzo Life Science), Tiron (Sigma-Aldrich), Z-VAD-FMK, Z-DEVD-FMK, Z-
IETD-FMK, Z-LEHD-FMK (BD biosciences), CA-074-Me (Calbiochem), GW4869 
(Calbiochem), Nec-1s (Calbiochem), diphenyleneiodonium (Calbiochem), ML141 (Santa 
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Cruz). The cells were then left untreated or were treated with GA101 for 6h and analyzed by 
flow cytometry after AV/PI labeling.  
2.4. ROS detection 
10
6
 cells were first pre-treated for 2h with different inhibitors: Latrunculin B, Tiron, DPI, or 
ML141, and then treated with GA101 and the ROS marker carboxy-H2DCFDA (25mM, 
Molecular Probes) for 30min, 1h, 3h, 6h or left untreated. Carboxy-H2DCFDA is oxidized in 
the presence of ROS to carboxy-DCF, which emits green fluorescence. ROS detection was 
analyzed by flow cytometry and data were processed using the FlowJo software.  
2.5. Subcellular fractionation 
Cells (4x10
7
) were harvested 4h after treatment with GA101 and rinsed in cold SET buffer 
(250mM sucrose, 1mM EDTA, 10mM Tris, pH 7.4) by centrifugation at 1200rpm for 5min. 
Cells were resuspended in 0.5mL of cold SET buffer containing ETDA-free anti-protease 
cocktail (APC, Roche) and then subjected to 30 strokes on ice using a Dounce homogenizer. 
A centrifugation at 1000g at 4
o
C for 10min was performed to separate supernatant from 
cell/nuclei pellet. The supernatant was collected and the pellet was resuspended in 0.5mL of 
cold SET buffer containing APC. The suspension was then subjected to another 30 strokes 
and to centrifugation as described above. The supernatants were pooled and centrifuged at 
20000g, 4
o
C for 20 min. The pellet was washed with 1mL SET buffer containing APC and 
lysed with 50µL of lysis buffer (Thermo Scientific) to obtain a mitochondria/lysosome 
fraction. The supernatant was ultracentrifuged at 100000g at 4
o
C for 60 min. The supernatant 
(corresponding to the cytosol fraction) was collected and the pellet was resuspended in 50 µL 
of lysis buffer to obtain a vesicle-rich fraction. To obtain only the mitochondria/lysosome and 
cytosolic fractions, treated cells were subjected to the same protocol with SE buffer (250 mM 
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sucrose, 1mM EDTA, pH 7.4) instead of SET solution, skipping out the ultracentrifugation 
step.  
2.6. Antibodies 
Primary antibodies used were mouse anti-LAMP1 (Abcam), anti-bovine serum albumin 
(ab79872, Abcam), anti-PDK1 (ab110025, Abcam), anti-cytochrome C (MAB897, BD 
Pharmingen), anti-β-actin (A-5441, Sigma), anti-α-tubulin (sc-32293, Santa Cruz), and rabbit 
anti-cathepsin B (EML-SA361, Enzo), anti-cathepsin B (ab30443, Abcam), anti-cathepsin B 
(sc-13985, Santa Cruz), anti-cathepsin D (ab75852, Abcam), anti-AIF (551429, BD 
Pharmingen), anti-endonuclease G (3035, ProSci), anti-activated caspase-3 (9661, Cell 
Signaling), anti-caspase-3 (9662, Cell Signaling). Peroxidase-conjugated secondary 
antibodies were as follows: rabbit anti-mouse (P0161, Dako), and goat anti-rabbit (12-348, 
Millipore Corporation) antibodies. 
Supplementary Materials and Methods are available. 
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3. Results 
3.1. GA101 treatment induces rapid and sustained homotypic adhesion 
To test the effect of GA101 on cell-cell adhesion, we selected Raji cells, a prototypical 
chemoresistant BL-derived cell line expressing high level of CD20 (data not shown). As 
shown in Fig. 1, under normal culture conditions, Raji cells displayed a natural tendency to 
form clusters. Within 1h of treatment by GA101, adjacent cells underwent marked HA, 
forming large cellular aggregates. Rituximab also induced HA of Raji cells, with virtually 
similar kinetics. We also observed that the addition of GA101 or rituximab to SUDHL-4 cells, 
a human diffuse large B-cell lymphoma cell line, also triggered HA, albeit with distinct 
kinetics (GA101: ~ 1h; rituximab: ~ 4h) (Supplementary Fig. 1). Thus, although HA seems 
to be of larger amplitude and higher velocity with GA101, induction of this phenomenon is 
not restricted to this mAb and appears to be a shared property with rituximab. 
3.2. GA101-treated cells undergo cell death through a caspase-independent pathway 
Apoptosis and necrosis are two types of cell death with distinct morphological and 
biochemical features. Apoptotic cells are often characterized by fragmented nuclei, PS surface 
exposure, separation of cell fragments into apoptotic bodies, whereas necrotic cells are mainly 
defined by loss of plasma membrane integrity and swelling of cellular organelles including 
mitochondria [42]. Although programmed necrosis has been suggested to represent the major 
route to cell death in GA101-treated cells [38, 39], GA101 has also been reported to trigger 
cell death showing a mixture of hallmarks typically found in apoptosis and necrosis [15, 40]. 
To gain further insight into this issue, we performed dual staining with fluorescent Annexin V 
(AV) and propidium iodide (PI) (on mechanically dissociated cells) followed by flow 
cytometry to distinguish between apoptotic and necrotic cell populations following treatment 
by GA101. In this test, AV+ (positive)/PI- (negative) cells are classically considered as 
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apoptotic cells and PI+cells as necrotic cells. However, it is the movement of cells from AV-
/PI- status (viable) to AV+/PI- (early apoptotic cells with membrane integrity) and eventually 
to AV+/PI+ (end stage apoptosis or secondary necrosis, with plasma membrane rupture) 
which is truly indicative of apoptosis (AV-/PI+ cells corresponding to primary necrotic cells). 
As shown in Fig. 2A, GA101 treatment reduced the viable cell fraction by 60% 6h post-
treatment. Approximately 20% of GA101-treated cells showed AV+/PI- staining at 6h, and 
the proportion of AV+/PI- cells gradually diminished to less than 2% at 48h post-treatment. 
The proportion of AV+/PI+ cells followed a similar pattern, whereas the percentage of AV-
/PI+ cells, which was about 4% at 6h, roughly doubled during the assessed time points to 
reach 30% at 48h. Rituximab was less efficient than GA101 in inducing the death of Raji cells 
and AV+/PI+ dead cells were only marginally detected after treatment with this antibody (Fig. 
2A). Our results indicate that GA101 addition did not result in the classical phenotypic pattern 
of cells transitioning from early apoptosis to late apoptosis and necrosis.  
Pre-treatment with a pan-caspase chemical inhibitor or with caspase selective inhibitors had 
almost no effect on the proportion of cells stained with AV and/or PI (Fig. 2B), further 
suggesting that this cell death is not induced through a caspase-dependent apoptotic pathway. 
These observations suggest that either (i) GA101 promotes caspase-independent apoptosis in 
a subpopulation of Raji cells and necrosis in another subpopulation of the cell culture, (ii) or 
that the process by which cells undergo their demise exhibit both apoptotic-like and necrotic-
like signatures. Note that induction of cell death by GA101 also appears to be independent of 
RIPK1 (a necrosis mediator) or sphingomyelinase (an apoptotic mediator) activity 
(Supplementary Fig. 2). 
3.3. Inhibition of actin remodeling and oxidative damage but not of cathepsin B 
activity can protect cells against GA101-induced cell death 
11 
 
Reorganization of cortical actin cytoskeleton and production of ROS by NOX following 
cytosolic release of active cathepsin B from lysosomes have been suggested to play a key role 
in GA101-induced cell death of B-lymphoma cells [38, 39]. Here, we examined the effect of 
inhibiting actin polymerization (with Latrunculin B, Lat B), cathepsin B activity (with CA-
074-Me, a membrane-permeable selective inhibitor of this enzyme) or ROS function (by 
using the ROS scavenger Tiron) on the death of Raji cells cultured in presence of GA101. As 
shown in Fig. 2C, the death of GA101-treated cells was fully prevented when the cells were 
pre-treated with LatB, confirming the upstream role of actin remodeling in the death cascade. 
Pre-treatment with Tiron partially reduced cell mortality after GA101 treatment, mainly by 
decreasing the percentage of AV+/PI+ (27%) and AV-/PI+ cells (11%). In contrast, pre-
treatment with CA-074-Me could not rescue Raji cells from GA101-induced death (Fig. 2C).  
These results demonstrate that actin reorganization and ROS production are involved in the 
induction of cell death by GA101, but challenge a role for cathepsin B in this process. We 
thus decided to undertake biochemical experiments to formally determine whether or not 
LMP and/or MMP occur in response to GA101 addition. 
3.4. MMP and LMP do not occur in response to GA101 
To determine whether MMP takes place during GA101-induced cell death, we analyzed the 
localization of a panel of mitochondrial proteins following GA101 treatment: PDK1, a 
mitochondrial matrix protein, and Cytochrome c (Cyt-c), Endonuclease G (EndoG) and AIF, 
three mitochondrial intermembrane proteins respectively involved in apoptosis (Cyt-c) or 
caspase-independent cell death (EndoG, AIF). Untreated cells and GA101-treated cells were 
subjected to subcellular fractionation to obtain a fraction enriched in mitochondria and 
lysosomes (Mito/Lyso) and a cytosolic fraction. As shown in Fig. 3A, at each time point, the 
abundance of PDK1, Cyt-c, EndoG and AIF in the Mito/Lyso fraction of GA101-treated cells 
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was nearly identical to that found in the Mito/Lyso fraction of untreated cells. Importantly, no 
significant release of these proteins into the cytosol or change in their amount in the 
Mito/Lyso fraction was detected with GA101-treated cells (except for EndoG, which was 
slightly more abundant in the Mito/Lyso fraction following GA101 treatment). Similarly, 
there was no observable increase in the quantity of active caspase-3 in the cytosolic fraction 
of GA101-treated cells, compared to controls (Fig. 3A). UVB-induced cleavage of caspase-3 
and cytosolic release of Cyt-c were used as positive controls for MMP (Supplementary Fig. 
3). Collectively, these data indicate that GA101 treatment did not trigger MMP and 
processing of the effector caspase-3.  
In parallel, we analyzed if LMP, assessed by the release of active cathepsin B from lysosomes 
into the cytosol, occurred following GA101 treatment. Because cathepsin B can be detected in 
non-lysosomal compartments such as secretory granules [43-45], subcellular fractionation 
was conducted using lysates from untreated cells or GA101-treated cells to generate a 
cytosolic fraction, a Mito/Lyso fraction and a fraction containing vesicles (including Golgi- or 
microtubule-associated vesicles, endosomal and secretory vesicles). Cathepsin B usually 
exists as three forms: two pro-enzyme forms (38 kDa and 44 kDa, respectively) and an active 
form (31 kDa) [46, 47]. As shown in Fig. 3B, in untreated cells, active cathepsin B was 
detected in the Mito/Lyso and vesicle fractions but not in the cytosolic fraction. However, 
contrary to expectations, active cathepsin B was not found in the cytosolic fraction following 
GA101 treatment. This observation was extended to another lysosomal protein, cathepsin D, 
which like cathepsin B was not released from lysosomes to the cytosol upon exposure to 
GA101 (Fig. 3B) (note that cytosolic release of cathepsin D was observed after H2O2 
treatment, see Supplementary Fig. 4). In addition, in contrast to a previous report [38], active 
cathepsin B was not released into the extracellular medium after GA101 treatment. Like 
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cathepsin B, the active form of cathepsin D was also undetectable in the extracellular medium 
derived from GA101-treated samples (Fig. 4A, upper panel, lanes 1-6).  
Taken together, these results demonstrate that based on biochemical experiments, MMP and 
LMP do not occur in cells in response to GA101 treatment. 
3.5. Polyclonal antibody ab30443 non-specifically binds to GA101 
Our findings showing that GA101 does not trigger neither MMP nor LMP were in conflict 
with previously published data [38]. One possible explanation for this discrepancy was the 
use of different antibodies against cathepsin B. The authors of the above-cited publication 
used a rabbit serum polyclonal anti-cathepsin B antibody (ab30443) purchased from the 
Abcam company (Dr. Honeychurch, personal communication), while we used a commercial 
rabbit polyclonal antibody from Santa Cruz (sc-13985). As shown in Fig. 5A, antibody 
ab30443 revealed a clear signal at around 30 kDa when tested by western blot on the 
Mito/Lyso fractions derived from GA101-treated cells. This antibody also gave a positive 
signal with the extracellular medium (Fig. 5B) but not the cytosolic fraction of cells treated 
with GA101 (Fig. 5A), a result seemingly consistent with previously published observations 
[38]. However, quite surprisingly, a signal of identical molecular mass was also detected in 
samples of pure culture medium conditioned with GA101 in the complete absence of cells 
(Fig. 4A, lower panel, lanes 7-9). Furthermore, when we treated CD20-negative Jurkat cells 
with GA101 (i.e., human T lymphocytes which are not expected to react to GA101), we still 
observed a strong signal in the extracellular medium sample when probing the membrane with 
antibody ab30443 but not with antibody sc-13985 (Fig. 4B). A reasonable explanation for this 
unexpected finding is that ab30443 antibodies actually recognize GA101 chains (presumably 
the light chain which has an estimated MW of 24 kDa, CHEMBL1743048) instead of (or in 
addition to) cathepsin B. 
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In support to this hypothesis, we showed by immunofluorescence that ab30443 stained the 
surface and the pericortical region of GA101-treated Raji cells, and that this staining did not 
colocalize with the lysosomal compartment (Supplementary Fig. 5, upper panels). In 
contrast, by using the antibody sc-13985 specific to cathepsin B, we obtained a cytoplasmic 
labeling of cathepsin B in both non-treated and GA101-treated cells. In both cell populations, 
this antibody yielded a staining pattern consistent with partial colocalization with the 
lysosomal marker LAMP-1 (Supplementary Fig. 5, bottom panels).  
During the course of this study, we also found that, in addition to ab30443, another 
commercially available rabbit serum polyclonal anti-cathepsin B antibody, EML-SA361, has 
an irrelevant specificity towards GA101 antibody chains (Supplementary Table 1, Fig. 4A, 
lower panel, lanes 7-9 and Supplementary Fig. 6). Altogether, our data point to major issues 
in the specificity of several commercial antibodies directed against cathepsin B when they are 
used in experiments in which GA101 or other related antibodies are present. 
3.6. The activation status of major signaling and apoptotic molecules is only 
minimally modified by GA101 exposure 
Since GA101-induced cell death did not seem to require MMP or LMP, we were interested in 
dissecting upstream signaling events that link GA101-CD20 ligation and commitment to cell 
death. We used a protein array strategy to examine the activation status of key signaling 
molecules at baseline or after treatment with GA101. Changes in the phosphorylation of 
various well-known actors of survival- and apoptosis-regulatory pathways were analyzed at 
different time after antibody addition. The phosphorylation levels of most of the analyzed 
proteins did not vary in response to GA101, compared to untreated samples (Supplementary 
Fig. 7). 
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3.7. Possible involvement of the Rho GTPase Cdc42 and NOX-dependent ROS 
production in GA101-induced cytotoxicity  
We next devoted efforts to investigate the link between the early response (actin remodeling 
and HA) of B-lymphoma cells to GA101 and subsequent cell death events (i.e. increased 
oxidative stress). It has been reported that Cdc42, a member of the Rho family of GTPases, 
regulates actin reorganization and NOX-mediated ROS production [48], and can be activated 
in response to several cytotoxic chemicals (e.g. arsenic, ethanol and mycophenolic acid) [49-
51]. Therefore, we investigated a potential role of Cdc42 in GA101-induced HA and cell 
death. Pre-treatment with the Cdc42 GTPase inhibitor ML141 or with the NOX inhibitor DPI 
prevented HA of Raji cells treated by GA101 (Supplementary Fig. 8A) and partially rescued 
these cells from GA101-induced cell death (Supplementary Fig. 8B). Pre-incubation with 
Lat B or DPI significantly reduced ROS production at 3h and 6h post-treatment, compared to 
cells pre-incubated with DMSO. In contrast, pre-treatment with ML141 could not prevent 
ROS production and even exacerbated it (Supplementary Fig. 8C). These results based on 
the use of chemical inhibitors suggest that in response to GA101 (i) the activities of Cdc42 
and NOX may be involved in the induction of cell death; (ii) both actin remodeling and NOX 
activity may be implicated in HA and ROS production; (iii) Cdc42 activity may control HA 
but not ROS production.  
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4. Discussion 
Previous studies on human cellular models have produced ambiguous results about the 
modality by which B-cells die in vitro upon GA101 treatment [15, 38-41], leaving the process 
of GA101-induced cell killing unclear. The aim of our study was to clarify the mode of cell 
death induced by GA101 in vitro, and in particular the potential involvement of lysosomal 
(LMP) and mitochondrial permeabilization (MMP) events. We provided definitive evidence 
that GA101 triggers HA and death of B-cells in culture, two processes absolutely dependent 
on actin remodeling and involving ROS production, as previously published [38, 39]. Our 
results showed that GA101 triggers a form of caspase-independent cell death exhibiting both 
apoptotic and necrotic features, also consistent with previous reports [38, 40]. 
Unexpectedly, by using biochemical techniques, we failed to detect clear evidence of MMP 
and LMP in GA101-treated cells, contrary to the literature [38, 39, 41]. In previous reports, 
LMP was inferred partly based on increased Lysotracker red or acridin orange stainings [38, 
39]. However, general decrease in intracellular pH (as detected by lysotracker or acridine 
orange and incorrectly defined as LMP) might or might not be accompanied by LMP. The 
second argument in support of LMP relates to the fact that cathepsin B was seemingly 
detected in the extracellular medium of GA101-treated cells, contrary to Rituximab-treated 
cells or control cells (see Figure 6C in [38]; but note that signal saturation is obvious for BSA 
in the GA101 lane compared to Rituximab, resulting in a wrong quantitation of Cathepsin B 
signals). Increased cathepsin D expression was also previously reported in GA101-treated 
multicellular aggregates of lymphoma cells [41], but experiments were made using total cell 
lysates (prior to western blot analysis) (Dr. Bezombes, personal communication) and therefore 
do not provide any information as to whether cathepsin D was genuinely released from 
lysosomes. In our hands, lysosomal release of cathepsins B and D, assessed using specific 
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antibodies after cell fractionation, was not observed in GA101-treated Raji or SUDHL-4 cells. 
We therefore argue that lack of specificity of the commercial ab30443 antibody against 
cathepsin B probably resulted in misleading interpretations of cathepsin B release from 
lysosomes or secretion into the extracellular medium in response to GA101 treatment. This 
unexpected finding challenges current assumptions about the action mode of GA101 [38, 39, 
41].  
5. Conclusions 
Although GA101 represents a promising new option for patients with B-cell malignancies, its 
mechanism of action remains enigmatic, at least in vitro. GA101-CD20 ligation is followed 
by an asynchronous process of cell mortality that do not strictly conform the criteria of 
apoptosis or programmed necrosis, two genetically-determined programs of cell death. The 
fact that HA represents a linchpin in GA101 action mode suggests that direct plasma-
membrane-associated events (e.g. Cdc42 and NOX activities), physical stress due to HA or 
aggregation-induced aberrant genetic expression might play a role in the death sentence.  
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Figure legends  
Figure 1: GA101 or rituximab induce homotypic adhesion of Raji cells. 
Microphotographs of control cells and cells treated with GA101 or rituximab (10 µg/ml) were 
taken at 1, 4, 8, 12 and 20 h post-treatment using phase contrast videomicroscopy (Objective: 
10x, scale bar: 100 µm). Identical experiments were carried out using SUDHL-4 cells leading 
to similar results (not shown). 
Figure 2: Cell death induced by GA101 is independent of both caspase and cathepsin B 
activities but involves actin polymerization and ROS production. Flow cytometric 
analysis of Annexin-V (AV) and propidium iodide (PI) staining of Raji cells. (A) Cells were 
treated with GA101 or rituximab (10 µg/ml) for 6, 12, 24 and 48 h. Untreated cells were 
prepared at each time point as controls. (B) Cells were incubated with 40 µM of broad-
spectrum caspase inhibitor (Z-VAD-FMK), caspase-3 inhibitor (Z-DEVD-FMK), caspase-8 
inhibitor (Z-IETD-FMK) or caspase-9 inhibitor (Z-LEHD-FMK) for 1 h and then treated with 
10 µg/ml of GA101 for 6 h. Cells treated with DMSO were prepared as controls. (C) Cells 
were pre-treated with 20 µM of actin polymerization inhibitor (Latrunculin B, LatB), 20 mM 
ROS scavenger (Tiron) or 200 µM cathepsin B inhibitor (CA-074-Me) for 1 h and then 
treated with 10 µg/ml of GA101 or 0.5 mM H2O2 for 6h. Cells treated with DMSO were 
prepared as controls. 
Figure 3: MMP and LMP do not occur following GA101 treatment. (A) Cells were left 
untreated or treated with 10 µg/ml of GA101 for 6, 12 or 24 h, and subcellular fractionation 
followed by western blot analysis was performed. Abundance of the assayed mitochondrial 
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proteins in the mitochondria/lysosome (Mito/Lyso) fraction and in the cytosolic fraction was 
analyzed by western blotting. The MW (kDa) of each protein is indicated. At each time point, 
the abundance of PDK1, cytochrome C, Endonuclease G, and AIF in the Mito/Lyso fraction 
of GA101-treated Raji cells was similar to that found in the Mito/Lyso fraction of untreated 
cells. The presence of these proteins only in the Mito/Lyso fraction but not in the cytosolic 
fraction shows that subcellular fractionation was successful. No significant increase was 
observed in the quantity of the assayed proteins or in that of active caspase-3 in the cytosolic 
fraction of GA101-treated Raji cells, compared to controls. Note that actin, which was used as 
control for equal loading, was less abundant in the Mito/Lyso fraction after GA101 addition. 
(B) Cells were left untreated or treated with 10 µg/ml of GA101 for 6 h, followed by 
subcellular fractionation. Abundance of lysosomal-associated membrane protein 1 (LAMP1), 
cathepsin B (labeled using antibody sc-13985) and cathepsin D in the mitochondria/lysosome 
(Mito/Lyso) fraction, in the cytosolic fraction and in the vesicle-rich fraction was analyzed by 
western blot. The MW (kDa) of each protein is indicated. NT: non-treated, GA: GA101. 
Similar results were obtained using SUDHL-4 cells (not shown). 
Figure 4: Cathepsins B and D are not released into the extracellular medium of cultured 
B cells after GA101 treatment. Raji cells were left untreated or treated with 10 µg/ml of 
GA101 or rituximab for 6 h and cell lysates were prepared. Samples of the extracellular media 
of cultured cells treated with GA101 or rituximab were prepared as well as samples of pure 
fresh medium supplemented with GA101 or rituximab. Medium and protein samples were run 
on acrylamide gels for western blot analysis. (A) Upper panel: membranes were labeled using 
anti-cathepsin B antibody sc-13985 or anti-cathepsin D antibody. Lower panel: immunoblot 
using anti-cathepsin antibodies ab30443 or EML-SA361. (B) Jurkat cells were left untreated 
or were treated with 10 μg/mL of GA101 for 6 h. Cell lysates and extracellular media were 
collected for western blot analysis. Pure medium alone and medium containing 10 μg/mL of 
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GA101 were used as controls. Ab30443 antibody displays non-specific reactivity toward 
GA101. In contrast, sc-13985 antibody specifically recognizes cathepsin B. NT: non-treated, 
Rt: rituximab, GA: GA101, BSA: bovine serum albumin, a component of fetal bovine serum 
used in culture medium preparation. The MW (kDa) of each protein is indicated.  
Figure 5: Antibody Ab30443 exhibits non-specific reactivity towards GA101. (A) Raji 
cells were left untreated or treated with 10 µg/ml of GA101 for 6, 12, 24 h, followed by 
subcellular fractionation and western blot analysis. Abundance of the assayed lysosomal 
proteins in the mitochondria/lysosome (Mito/Lyso) fraction and in the cytosolic fraction was 
analyzed by western blot. (B) Samples of extracellular media of untreated or GA101-treated 
cells were collected for western blot analysis. The signal obtained is identical to (A), 
indicating that ab30443 recognizes the GA101 antibody and not a cellular protein (such as 
lysosomal Cathepsin B). *: membranes labeled using antibody ab30443.  
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Figure 1: GA101 or rituximab induce homotypic adhesion of Raji cells. Microphotographs of 
control cells and cells treated with GA101 or rituximab (10 µg/ml) were taken at 1, 4, 8, 12 and 
20 h post-treatment using phase contrast videomicroscopy (Objective: 10x, scale bar: 100 µm). 
Identical experiments were carried out using SUDHL-4 cells leading to similar results (not 
shown). 
 
Figure 1 Legend
Figure 2: Cell death induced by GA101 is independent of both caspase and cathepsin B 
activities but involves actin polymerization and ROS production. Flow cytometric analysis of 
Annexin-V (AV) and propidium iodide (PI) staining of Raji cells. (A) Cells were treated with 
GA101 or rituximab (10 µg/ml) for 6, 12, 24 and 48 h. Untreated cells were prepared at each time 
point as controls. (B) Cells were incubated with 40 µM of broad-spectrum caspase inhibitor (Z-
VAD-FMK), caspase-3 inhibitor (Z-DEVD-FMK), caspase-8 inhibitor (Z-IETD-FMK) or 
caspase-9 inhibitor (Z-LEHD-FMK) for 1 h and then treated with 10 µg/ml of GA101 for 6 h. 
Cells treated with DMSO were prepared as controls. (C) Cells were pre-treated with 20 µM of 
actin polymerization inhibitor (Latrunculin B, LatB), 20 mM ROS scavenger (Tiron) or 200 µM 
cathepsin B inhibitor (CA-074-Me) for 1 h and then treated with 10 µg/ml of GA101 or 0.5 mM 
H2O2 for 6h. Cells treated with DMSO were prepared as controls. 
 
Figure 2 Legend
Figure 3: MMP and LMP do not occur following GA101 treatment. (A) Cells were left 
untreated or treated with 10 µg/ml of GA101 for 6, 12 or 24 h, and subcellular fractionation 
followed by western blot analysis was performed. Abundance of the assayed mitochondrial 
proteins in the mitochondria/lysosome (Mito/Lyso) fraction and in the cytosolic fraction was 
analyzed by western blotting. The MW (kDa) of each protein is indicated. At each time point, the 
abundance of PDK1, cytochrome C, Endonuclease G, and AIF in the Mito/Lyso fraction of 
GA101-treated Raji cells was similar to that found in the Mito/Lyso fraction of untreated cells. 
The presence of these proteins only in the Mito/Lyso fraction but not in the cytosolic fraction 
shows that subcellular fractionation was successful. No significant increase was observed in the 
quantity of the assayed proteins or in that of active caspase-3 in the cytosolic fraction of GA101-
treated Raji cells, compared to controls. Note that actin, which was used as control for equal 
loading, was less abundant in the Mito/Lyso fraction after GA101 addition. (B) Cells were left 
untreated or treated with 10 µg/ml of GA101 for 6 h, followed by subcellular fractionation. 
Abundance of lysosomal-associated membrane protein 1 (LAMP1), cathepsin B (labeled using 
antibody sc-13985) and cathepsin D in the mitochondria/lysosome (Mito/Lyso) fraction, in the 
cytosolic fraction and in the vesicle-rich fraction was analyzed by western blot. The MW (kDa) 
of each protein is indicated. NT: non-treated, GA: GA101. Similar results were obtained using 
SUDHL-4 cells (not shown). 
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Figure 4: Cathepsins B and D are not released into the extracellular medium of cultured B 
cells after GA101 treatment. Raji cells were left untreated or treated with 10 µg/ml of GA101 
or rituximab for 6 h and cell lysates were prepared. Samples of the extracellular media of cultured 
cells treated with GA101 or rituximab were prepared as well as samples of pure fresh medium 
supplemented with GA101 or rituximab. Medium and protein samples were run on acrylamide 
gels for western blot analysis. (A) Upper panel: membranes were labeled using anti-cathepsin B 
antibody sc-13985 or anti-cathepsin D antibody. Lower panel: immunoblot using anti-cathepsin 
antibodies ab30443 or EML-SA361. (B) Jurkat cells were left untreated or were treated with 10 
μg/mL of GA101 for 6 h. Cell lysates and extracellular media were collected for western blot 
analysis. Pure medium alone and medium containing 10 μg/mL of GA101 were used as controls. 
Ab30443 antibody displays non-specific reactivity toward GA101. In contrast, sc-13985 antibody 
specifically recognizes cathepsin B. NT: non-treated, Rt: rituximab, GA: GA101, BSA: bovine 
serum albumin, a component of fetal bovine serum used in culture medium preparation. The MW 
(kDa) of each protein is indicated.  
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Figure 5: Antibody Ab30443 exhibits non-specific reactivity towards GA101. (A) Raji cells 
were left untreated or treated with 10 µg/ml of GA101 for 6, 12, 24 h, followed by subcellular 
fractionation and western blot analysis. Abundance of the assayed lysosomal proteins in the 
mitochondria/lysosome (Mito/Lyso) fraction and in the cytosolic fraction was analyzed by 
western blot. (B) Samples of extracellular media of untreated or GA101-treated cells were 
collected for western blot analysis. The signal obtained is identical to (A), indicating that 
ab30443 recognizes the GA101 antibody and not a cellular protein (such as lysosomal Cathepsin 
B). *: membranes labeled using antibody ab30443.  
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Supplementary Material and Methods 
Protein array 
Cells were treated with GA101 for 1 and 6h, and then subjected to protein array using 
PathScan® Stress and Apoptosis Signaling Antibody Array Kit and PathScan® Intracellular 
Signaling Array Kit (Cell Signaling), according to manufacturer’s instruction. In brief, 
GA101-treated cells were lysed in 100 µl of PathScan Sandwich ELISA lysis buffer (Cell 
Signaling) containing ETDA-free anti-protease cocktail (Roche). The supernatants were 
collected after a centrifugation at 14000g for 2 min. Array slides were incubated in blocking 
buffer for 15 min. Lysate (75 µl, 0.6 mg/ml) was dispensed into wells of array slide for 
overnight incubation at 4
°
C. Incubation in Detection Antibody Cocktail solution (75 µl) for 
1.5h and in HRP-linked Streptavidin solution (75 µl) for 45 min was then sequentially 
performed. Labeled proteins were detected by chemiluminescence using LumiGIO/Peroxide 
solution and recorded with LAS3000 software (Fujifilm). Spot intensities were analyzed using 
ImageJ Software. 
Membrane protein extraction 
5x10
6
 cells were harvested 4h after treatment with GA101 by centrifugation at 300g for 5 min. 
Untreated cells were used as controls. Cell pellets were washed with 3mL of Cell Wash 
Solution (Membrane Protein Extraction kit, Thermo scientific) and centrifuged at 300g for 5 
min. Supernatants were carefully removed and discarded. Cells were resuspended in 1.5mL of 
Cell Wash Solution and transferred to a 2mL centrifuge tube. Cells were centrifuged at 300g 
for 5 min and supernatants were discarded. 0.75mL of Permeabilization Buffer (Membrane 
Protein Extraction kit, Thermo scientific) was added to the cell pellets. Cell suspension was 
then incubated 10min at 4°C with constant mixing. After incubation, cells were centrifuged 
for 15min at 16000g. Supernatants containing cytosolic proteins were transferred into a new 
3 
 
tube. 0.5mL of Solubilization buffer (Membrane Protein Extraction kit, Thermo scientific) 
was added to the pellets in order to resuspend the cells. Tubes were then incubated at 4°C for 
30min with constant mixing. After incubation, cells were centrifuged at 16000g for 15min at 
4°C. Supernatants containing solubilized membrane and membrane-associated proteins were 
collected into a new tube.  The quantity of proteins in samples was estimated by Bradford 
assay using a Multiskan Spectrum plate reader at 595nm (Thermo Electro Corporation) and 
western blotting was performed.  
Western blotting 
Total cell lysates were prepared using RIPA lysis buffer containing ETDA-free anti-protease 
cocktail. The quantity of proteins in samples was estimated by Bradford assay. For SDS-
PAGE, 25-50µg of proteins were loaded onto NuPAGE 4-12% Bis-Tris (1.5 nm) gels (Novex, 
Life Technologies). Fractionation of cellular proteins was performed using MES buffer (Life 
technologies) at 200V for 40 min. Protein transfer was performed using iBlot Gel Transfer 
Stacks (nitrocellulose mini, Life Technologies). The protein bands were detected by 
chemiluminescence using Lumina Forte reagent (Millipore) and recorded with LAS3000 
software (Fujifilm). 
Immunocytochemistry 
Cells were spun on glass slides by centrifugation at 650rpm for 5min. Fixed cells were dried 
overnight at room temperature and stored at -20
o
C. Fixation and permeabilization were 
performed using 4% paraformaldehyde (at room temperature) and acetone (-20
o
C) for 10min, 
respectively, followed by incubation in blocking buffer (5% BSA in PBS) overnight at 4
o
C 
with gentle agitation. The cells were then labeled using mouse anti-LAMP-1 (ab25630, 
Abcam) and rabbit anti-cathepsin B antibody (sc-13985 from Santa-Cruz or ab30443 from 
Abcam) at room temperature for 1h, followed by incubation with donkey anti-mouse-
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Alexa568 (Invitrogen) and goat anti-rabbit-Alexa488 (Invitrogen) secondary antibodies, 
before a final wash in PBS containing 0.2% Tween-20. Fluorescence imaging 
microphotographs were taken using an Axiophot Zeiss epifluorescence microscope.  
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1: Homotypic adhesion of SUDHL-4 cells induced by GA101 or 
Rituximab. Microphotographs of untreated SUDHL-4 cells and cells treated with GA101 or 
Rituximab (10 µg/ml) were taken at 1, 4, 8, 12 and 20h post-treatment using phase contrast 
microscopy (Objective: 10x, scale bar: 100 µm). 
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Supplementary Figure 2: Chemical inhibition of RIPK1 and sphingomyelinase does not 
prevent cell death after GA101 exposure. Raji cells were incubated in presence of 20 µM of 
RIPK inhibitor (Nec-1s) or 2 µM of sphingomyelinase inhibitor (GW4869) for 1h and then 
treated with 10 µg/ml of GA101 for 6h. Cells treated with DMSO were prepared as controls. 
Treated cells were analyzed by flow cytometry after dual Annexin V (AV) – Propidium 
iodide (PI) staining. 
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Supplementary Figure 3. Cytosolic release of Cytochrome C and caspase-3 activation 
are detectable in UVB-treated Raji cells. 
Cells were left untreated or treated with 10 µg/ml of GA101 for 16 h and subcellular 
fractionation was then performed. Cells exposed to 50 mJ/cm
2
 UVB with or without 10 mM 
aspirin (Pique et al., 2000) were prepared as a positive control for apoptosis induction. 
Abundance of the assayed mitochondrial proteins in the mitochondria/lysosome (Mito/Lyso) 
fraction and in the cytosolic fraction was analyzed by western blotting. The MW (kDa) of 
each protein is indicated. VDAC is a mitochondrial membrane protein. The results indicate 
that in contrast to cells treated with GA101, cytosolic release of cytochrome C and cleavage 
of caspase-3 are observed in cells challenged with UBV or aspirin. 
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Supplementary Figure 4. Detection of cathepsin release in H2O2-treated cells. 
Raji cells were left untreated or treated with 10 µg/ml of GA101 or 0.05 mM H2O2 for 16 h, 
followed by subcellular fractionation. Abundance of lysosomal-associated membrane protein 
1 (LAMP1), cathepsin B (labeled using antibody sc-13985) and cathepsin D in the 
mitochondria/lysosome (Mito/Lyso) fraction, in the cytosolic fraction and in the vesicle-rich 
fraction was analyzed by western blot. The MW (kDa) of each protein is indicated. NT: non-
treated, GA: GA101. The presence of active cathepsin B and D proteins only in the Mito/Lyso 
fraction but not in the cytosol shows that LMP does not occur in response to GA101 treatment. 
H2O2 and UVB were used as positive controls for LMP and MMP respectively and produced 
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the expected outcome: cytosolic release of cathepsin D (see box in lane 7) and of active 
caspase-3 (box in lane 8), respectively. 
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Supplementary Figure 5: Immunocytochemical staining using anti-cathepsin B 
antibodies ab30443 and sc-13985. Untreated and GA101-treated cells were cytospinned and 
subsequently subjected to immunofluorescent labeling using an antibody directed against the 
lysosomal marker LAMP1 (red) and either ab30443 or sc-13985 (green), two antibodies 
produced to detect cathepsin B. The nucleus was stained using DAPI (blue). 
Microphotographs of labeled cells were taken under an Axiophot Zeiss epifluorescence 
microscope (Objective: 50 x Oil, scale bar: 15µM). These immunofluorescence data strongly 
suggest that ab30443 (as well as EML-SA36, see Supplementary Figure 6) recognizes 
GA101 itself, either localized at the cell surface after CD20 ligation or in the pericortical or 
subplasmalemmal region as a consequence of its cellular internalization. Note that staining 
was brighter at cell-cell junctions, suggesting that GA101-CD20 complexes actively 
participate to the HA process. 
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Supplementary Figure 6: Immunofluorescent labeling using the EML-SA361 antibody. 
Untreated and GA101-treated cells were cytospinned and subsequently subjected to 
immunofluorescent labeling using an antibody directed against the lysosomal marker LAMP1 
(red) and either EML-SA361 or ab30443 (green), two antibodies produced to detect cathepsin 
B. The nucleus was stained using DAPI (bleu). Microphotographs of labeled cells were taken 
under an Axiophot Zeiss epifluorescence microscope (Objective: 50 x Oil, scale bar: 15µM).  
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Supplementary Figure 7. The activation status of major signaling and apoptotic 
molecules remains stable upon GA101 exposure. Raji cells were left untreated or treated 
with 10 µg/ml of GA101 for 1 and 6h. Total cell lysates were prepared and subjected to 
intracellular signaling and apoptosis protein arrays using the PathScan® Intracellular and 
Apoptosis Signaling Antibody Array Kits. The expression of total or phosphorylated proteins 
was visualized using a chemiluminescent method. One negative (left-bottom) and three 
positive controls were set in the 4 corners of each membrane. NT: non-treated, GA: GA101. 
The pathways studied were: (1) MAPK-MEK/ERK (Erk1/2-Thr202/Tyr204); (2) MAPK-
p38/JNK (TAK-Ser412, p38-Thr180/Tyr182, SAPK/JNK-Thr183/Tyr185; HSP27-Ser78); (3) 
Jak/Src (Stat1/3-Tyr701/Try705); (4) mTORC1 (S6 ribosomal protein-Ser235/236, p70 S6 
kinase-Thr389); (5) mTORC2 (Akt-Thr308/Ser473, PRAS40-Thr246, Bad-Ser112/Bad136, 
GSK-3-Ser9); (6) AMPK (AMPKα-Thr172); (7) ATM/ATR (p53-Ser15, Chk1/Chk2-
Ser345/Thr68; Smad2-Ser465/467); (8) caspase (caspase-3/7 and PARP cleavage; Survivin); 
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(9) NF-κB/Rel (IκBα-Ser32/36). Our results indicate that the binding of GA101 to CD20 does 
not provoke a significant modification in the assayed signaling pathways. Only Thr246-
phosphorylated PRAS40 was reduced (by ~30%) in GA101-treated cells 6h after treatment. 
Of note, activation of caspases -3 and -7 was not detected in GA101-treated cells, confirming 
that GA101-induced cell death is caspase-independent. 
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Supplementary Figure 8: Involvement of Cdc42 GTPase and NOX activities in HA, ROS 
production and cell death induced in response to GA101. (A) Raji cells were incubated in 
presence of 20 µM of actin polymerization inhibitor (Latrunculin B, LatB), 20 mM of ROS 
scavenger (Tiron), 150 µM of NOX inhibitor DPI or 160 µM of cdc42 GTPase inhibitor 
ML141 for 2 h and then treated with 10 µg/ml of GA101 for 6 h. Cells treated with DMSO 
were prepared as controls. Microphotographs were taken using an inverted Leica microscope 
(objective: 10x, scale bar: 100 µm). (B) Raji cells were incubated in presence of 150 µM of 
NOX inhibitor DPI or 160 µM of Cdc42 GTPase inhibitor ML141 for 2 h and then treated 
with 10 µg/ml of GA101 for 6 h. Cells treated with DMSO were prepared as controls. Treated 
cells were analyzed by flow cytometry after dual AV/PI staining. (C) Raji cells were 
incubated in presence of 20 µM Lat B, 20 mM Tiron, 100 µM DPI or 160 µM ML141 for 2 h 
and then treated with 10 μg/mL of GA101 and the ROS marker carboxy-H2DCFDA (25mM) 
for 30min, 1h, 3h, 6h or left untreated. At each time point, cells were harvested to measure 
ROS production by flow cytometry.  
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Supplementary Table 1: Identification of the proteins recognized by the anti-cathepsin B 
antibody EML-SA361. A protein lysate of SUDHL-4 cells treated with 10 µg/ml of GA101 
was prepared and the EML-SA361 antibody was used to carry out immunoprecipitation. 
Proteins present in the immunoprecipitate were then analyzed by high-resolution mass 
spectrometry using a LTQ Velos mass spectrometer. 
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